Paul Whiteaker
Associate Professor
Neurobiology
Barrow Neurological Institute
United States of America
Biography
Dr. Whiteaker is a graduate of the University of Bath, in the United Kingdom. He performed postdoctoral training at the University of Colorado – Boulder before joining the faculty at Barrow Neurological Institute in 2008, where he is an associate professor. Dr. Paul Whiteaker has over two decades of experience working in nicotinic acetylcholine receptor research. More recently, he has established a research program to recapitulate the diversity of naturally expressed nicotinic receptors using heterologous expression systems. This research background has provided Dr. Whiteaker with a wealth of experience in devising, exploiting, and publishing on novel nicotinic model systems, pharmacological agents, and assays.
Research Interest
Nicotinic receptor subtypes structure and function studies, Development of novel pharmacological reagents, Development of high throughput-capable assays
Publications
-
1.Moretti M, Zoli M, George AA, Lukas RJ, Pistillo F, Maskos U, Whiteaker P, Gotti C. The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization. Molecular pharmacology. 2014 Sep 1;86(3):306-17.
2. Marks MJ, Grady SR, Salminen O, Paley MA, Wageman CR, McIntosh JM, Whiteaker P. α6β2*â€subtype nicotinic acetylcholine receptors are more sensitive than α4β2*â€subtype receptors to regulation by chronic nicotine administration. Journal of neurochemistry. 2014 Jul 1;130(2):185-98.
3. George AA, Lucero LM, Damaj MI, Lukas RJ, Chen X, Whiteaker P. Function of human α3β4α5 nicotinic acetylcholine receptors is reduced by the α5 (D398N) variant. Journal of Biological Chemistry. 2012 Jul 20;287(30):25151-62.
